Rivastigmine in the treatment of Alzheimer's disease: an update.
about
Update on the pharmacological treatment of Alzheimer's diseasesym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot studyCognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.Therapeutic Effects of TianDiJingWan on the Aβ 25-35-Induced Alzheimer's Disease Model RatsEffective components of Chinese herbs reduce central nervous system function decline induced by iron overload.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment.Switching cholinesterase inhibitors in older adults with dementia.Pharmacological treatment of Alzheimer disease.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological TreatmentThe coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory.Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration.Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.Baicalein improves behavioral dysfunction induced by Alzheimer's disease in rats.Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).Determination of Meserine, a new candidate for Alzheimer's disease in mice brain by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic and tissue distribution study.Synthesis of 9-Aminoacridine Derivatives as Anti-Alzheimer Agents.Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease.URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents
P2860
Q33836947-4DB58DF8-11F4-4BB2-833E-8E8138751BC7Q34591673-9CE1107D-D5B2-41E7-A1C0-4F3818D114DDQ35049824-4B191B17-8BF3-428E-A14B-1ED6A1B7104AQ35106861-8BD90A2E-6643-46B0-8DA6-D2BF2CC1BF87Q35169744-C8314AAC-ED0F-4646-8125-DDE39B62046DQ35746328-779CE72D-F65E-4D6B-8C71-ADCCD1E2B1EFQ37358548-E61ABF9B-77F4-4F6E-96E1-152C7113BA95Q37569276-E9B4DC1B-20DE-48E3-869A-D739A78177DFQ37806328-9D3153BB-4A6D-4D0D-9315-965B63ECF263Q37947768-12C2B09E-8AFB-4F52-B979-35D653486109Q38127470-8959C2A0-AC2E-462A-BA7A-BB7946EA382AQ38149130-00B9B090-8539-4695-B85A-C05723B2225EQ38210108-A3B4B32D-079B-44D4-889C-1A5215FA66FFQ38827171-D6A91CDD-2F56-4794-8B9F-C292919EA891Q38860110-2A3B4E7D-3FC8-4280-BFEB-B91D10692ADFQ39016614-914334A2-13DF-4888-92BC-36E90141EFBEQ39398227-71067F4C-30FE-44B9-A970-7A378EFA50A0Q39477637-EE627B9C-7F8B-467E-977A-CCE64E2E706AQ40964337-9EB54AC7-3440-4FC9-BB09-C15A060F1B77Q42352199-CD29E64B-BC6C-4D61-A117-4C0C2D49B24DQ43954906-7F227F8D-EDB2-4A62-A0D3-570B3B9BEBE4Q47117179-D322E504-8F8F-4949-8066-1CC70E58CD33Q47951435-45A69194-57FA-4D69-BE50-1793EB94C136Q48074095-7F9CA38C-6B0B-4C4D-93EC-E082B1E32047Q53351906-D6789424-3ED6-45EC-89B2-F4818A69B9D1Q53368216-32938726-EAC6-4841-9DF7-6F5C2A53A7A5Q53462932-5D1D6EB4-A8D1-40F4-927E-F680B3AA43BEQ54979695-19E841BB-B76B-41E7-B782-3AC9E20E91E4Q58794595-20FF1D33-289F-4924-9F59-46E81C668EF6
P2860
Rivastigmine in the treatment of Alzheimer's disease: an update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rivastigmine in the treatment of Alzheimer's disease: an update.
@en
Rivastigmine in the treatment of Alzheimer's disease: an update.
@nl
type
label
Rivastigmine in the treatment of Alzheimer's disease: an update.
@en
Rivastigmine in the treatment of Alzheimer's disease: an update.
@nl
prefLabel
Rivastigmine in the treatment of Alzheimer's disease: an update.
@en
Rivastigmine in the treatment of Alzheimer's disease: an update.
@nl
P2860
P356
P1476
Rivastigmine in the treatment of Alzheimer's disease: an update.
@en
P2093
Maria Luisa Onor
Marianna Trevisiol
P2860
P356
10.2147/CIIA.2007.2.1.17
P407
P577
2007-01-01T00:00:00Z